北京大学人民医院是位于中国北京市的三级甲等医院，同时承担北京大学第二临床医学院的任务。医院有多个院区。

During the past decade, Peking University Institute of Hematology conducted 26 clinical trials. In the 10-year time frame, 26 clinical trials started and 2 clinical trials were completed, i.e. on average, 7.7% percent of trials that started reached the finish line to date. In the past 5 years, 15 clinical trials started and 2 clinical trials were completed. i.e. 13.3% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Peking University Institute of Hematology" #1 collaborator was "Beijing Hospital" with 2 trials as a collaborator, "Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China" with 2 trials as a collaborator, "Beijing Friendship Hospital" with 1 trials as a collaborator, "Cellular Biomedicine Group Ltd." with 1 trials as a collaborator and "China-Japan Friendship Hospital" with 1 trials as a collaborator. Other collaborators include 1 different institutions and companies that were collaborators in the rest 11 trials.

According to Clinical.Site data, the most researched conditions in "Peking University Institute of Hematology" are "Leukemia" (5 trials), "Immune Thrombocytopenia" (4 trials), "Stem Cell Transplant Complications" (3 trials), "Acute Leukemia" (2 trials) and "Allogeneic Hematopoietic Stem Cell Transplantation" (2 trials). Many other conditions were trialed in "Peking University Institute of Hematology" in a lesser frequency.

Most popular intervention types in "Peking University Institute of Hematology" are "Drug" (20 trials), "Biological" (4 trials), "Other" (2 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Decitabine" (2 trials), "Interferon Alfa-2b" (2 trials), "Methotrexate" (2 trials), "mBU/CY" (2 trials) and "mBU/CY and ATG" (2 trials). Other intervention names were less common.

The vast majority of trials in "Peking University Institute of Hematology" are 28 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Peking University Institute of Hematology". 1 are not yet recruiting, 10 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 3 completed trials in Peking University Institute of Hematology, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Peking University Institute of Hematology, 4 "Phase 1" clinical trials were conducted, 13 "Phase 2" clinical trials and 4 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 8 trials that are defined as “Not Applicable".